Quantum Genomics is launching a public equity offering on Alternext Paris, above all to fund the phase IIa clinical trials of its antihypertensive drug candidate QGC001

Quantum Genomics (Alternext – FR0011648971 – ALQGC) announces the launch of a public equity offering of approximately 9.1 M€ on the Alternext market, part of Euronext Paris.

  •      > Capital increase of approximately 9.1 M€,
  •      > Purchase agreement with shareholders for a maximum of €5 M
  •      > Indicative price range: €5.40 – €6.30
  •      > Subscription period from 27 January to 12 February 2015

 

Download press release